Arthur Driscoll

USPTO Granted Patents = 16 (Patent Applications = 15)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 432(Granted Patents)

Company Filing History:

7 out of 23

Confluent Surgical, Inc.

patents

5 out of 18

Ocular Therapeutix, Inc.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12357565 - Ocular implant containing a tyrosine kinase inhibitor (2025-07-15),

2. 12329853 - Compositions and methods for treating ocular diseases (2025-06-17),

3. 12171869 - Intracameral drug delivery depots (2024-12-24),

4. 11622935 - Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles (2023-04-11),

5. 11534396 - Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor (2022-12-27),

6. 11439592 - Ocular implant containing a tyrosine kinase inhibitor (2022-09-13),

7. 10617563 - Coated implants (2020-04-14),

8. 8889889 - Crosslinked polymers with the crosslinker as therapeutic for sustained release (2014-11-18),

9. 8888749 - Spray for fluent materials (2014-11-18),

10. 8440309 - Crosslinked polymers with the crosslinker as therapeutic for sustained release (2013-05-14),

11. 8387899 - Silicone spray tip (2013-03-05),

12. 8376989 - Compartmented syringe (2013-02-19),

13. 8360765 - Systems and method for forming a coaxial implant (2013-01-29),

14. 8152777 - Spray for fluent materials (2012-04-10),

15. 8033483 - Silicone spray tip (2011-10-11),

Title: The Innovative Contributions of Arthur Driscoll

Introduction

Arthur Driscoll, an accomplished inventor based in Reading, MA, has made significant strides in the field of ocular therapeutics. With a remarkable portfolio of 16 patents to his name, Driscoll's work focuses primarily on improving treatments for ocular diseases, showcasing his dedication to advancing medical science.

Latest Patents

Among his latest innovations is the patent for an ocular implant containing a tyrosine kinase inhibitor. This invention pertains to a sustained release biodegradable ocular implant designed to treat retinal diseases over extended periods. Another notable patent is centered on compositions and methods for treating ocular diseases, emphasizing the intracameral administration of a biodegradable implant that releases medication gradually. These inventions reflect Driscoll’s innovative approach to addressing complex ocular conditions.

Career Highlights

Driscoll has contributed his expertise to various prominent companies, including Confluent Surgical, Inc., and Ocular Therapeutix, Inc. His work in these firms has been integral to the development of cutting-edge solutions aimed at enhancing patient outcomes in eye care.

Collaborations

Throughout his career, Driscoll has collaborated with notable professionals such as Charles D. Blizzard and Peter K. Jarrett. These collaborations have facilitated the exchange of ideas and fostered innovation in the field of ocular treatments.

Conclusion

Arthur Driscoll's inventive spirit and commitment to improving ocular health have undoubtedly left a mark on the medical field. His patents are not just a testament to his skills as an inventor, but also to his dedication to enhancing patient care and experiences through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.